| Host: | Rabbit |
| Applications: | WB/ELISA |
| Reactivity: | Human |
| Note: | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Clonality: | Monoclonal |
| Clone ID: | SRM |
| Conjugation: | Unconjugated |
| Isotype: | IgG |
| Formulation: | PBS with 0.09% Sodium Azide, 0.05% BSA, 50% Glycerol, pH 7.3. |
| Purification: | Affinity purification |
| Concentration: | Lot specific |
| Dilution Range: | WB:1:9000-1:54000ELISA:Recommended starting concentration is 1 Mu g/mL. Please optimize the concentration based on your specific assay requirements. |
| Gene Symbol: | FGF23 |
| Gene ID: | 8074 |
| Uniprot ID: | FGF23_HUMAN |
| Immunogen Region: | 25-251 aa |
| Specificity: | Recombinant fusion protein containing a sequence corresponding to amino acids 25-251 of human FGF23 (NP_065689.1). |
| Immunogen Sequence: | YPNASPLLGSSWGGLIHLYT ATARNSYHLQIHKNGHVDGA PHQTIYSALMIRSEDAGFVV ITGVMSRRYLCMDFRGNIFG SHYFDPENCRFQHQTLENGY DVYHSPQYHFLVSLGRAKRA FLPGMNPPPYSQFLSRRNEI PLIHFNTPIPRRHTRSAEDD SERDPLNVLKPRARMTPAPA SCSQELPSAEDNSPMASDPL GVVRGGRVNTHAGGTGPEGC RPFAKFI |
| Tissue Specificity | Expressed in osteogenic cells particularly during phases of active bone remodeling. In adult trabecular bone, expressed in osteocytes and flattened bone-lining cells (inactive osteoblasts). |
| Post Translational Modifications | Following secretion this protein is inactivated by cleavage into a N-terminal fragment and a C-terminal fragment. The processing is effected by proprotein convertases. O-glycosylated at Thr-171 and Thr-178 by GALNT3 and glycosylation of Thr-178 requires previous glycosylation at Thr171. Glycosylation is necessary for secretion.it blocks processing by proprotein convertases when the O-glycan is alpha 2,6-sialylated. Competition between proprotein convertase cleavage and block of cleavage by O-glycosylation determines the level of secreted active FGF23. Phosphorylation at Ser-180 mediated by FAM20C slows down glycosylation at Thr-178 notably. |
| Function | Regulator of phosphate homeostasis. Inhibits renal tubular phosphate transport by reducing SLC34A1 levels. Up-regulates EGR1 expression in the presence of KL. Acts directly on the parathyroid to decrease PTH secretion. Regulator of vitamin-D metabolism. Negatively regulates osteoblast differentiation and matrix mineralization. |
| Protein Name | Fibroblast Growth Factor 23Fgf-23PhosphatoninTumor-Derived Hypophosphatemia-Inducing Factor Cleaved Into - Fibroblast Growth Factor 23 N-Terminal Peptide - Fibroblast Growth Factor 23 C-Terminal Peptide |
| Database Links | Reactome: R-HSA-109704Reactome: R-HSA-1257604Reactome: R-HSA-1839122Reactome: R-HSA-1839130Reactome: R-HSA-190322Reactome: R-HSA-190372Reactome: R-HSA-190373Reactome: R-HSA-190374Reactome: R-HSA-190375Reactome: R-HSA-2033519Reactome: R-HSA-2219530Reactome: R-HSA-381426Reactome: R-HSA-5654219Reactome: R-HSA-5654221Reactome: R-HSA-5654227Reactome: R-HSA-5654228Reactome: R-HSA-5654687Reactome: R-HSA-5654688Reactome: R-HSA-5654689Reactome: R-HSA-5654693Reactome: R-HSA-5654695Reactome: R-HSA-5654699Reactome: R-HSA-5654700Reactome: R-HSA-5654704Reactome: R-HSA-5654706Reactome: R-HSA-5654710Reactome: R-HSA-5654712Reactome: R-HSA-5654719Reactome: R-HSA-5654720Reactome: R-HSA-5654726Reactome: R-HSA-5654727Reactome: R-HSA-5654732Reactome: R-HSA-5654733Reactome: R-HSA-5655253Reactome: R-HSA-5655302Reactome: R-HSA-5655332Reactome: R-HSA-5658623Reactome: R-HSA-5673001Reactome: R-HSA-6811558Reactome: R-HSA-8957275 |
| Cellular Localisation | SecretedSecretion Is Dependent On O-Glycosylation |
| Alternative Antibody Names | Anti-Fibroblast Growth Factor 23 antibodyAnti-Fgf-23 antibodyAnti-Phosphatonin antibodyAnti-Tumor-Derived Hypophosphatemia-Inducing Factor Cleaved Into - Fibroblast Growth Factor 23 N-Terminal Peptide - Fibroblast Growth Factor 23 C-Terminal Peptide antibodyAnti-FGF23 antibodyAnti-HYPF antibodyAnti-UNQ3027 antibodyAnti-PRO9828 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
